#ariba_ref_name	ref_name	gene	var_only	flag	reads	cluster	ref_len	ref_base_assembled	pc_ident	ctg	ctg_len	ctg_cov	known_var	var_type	var_seq_type	known_var_change	has_known_var	ref_ctg_change	ref_ctg_effect	ref_start	ref_end	ref_nt	ctg_start	ctg_end	ctg_nt	smtls_total_depth	smtls_nts	smtls_nts_depth	var_description	free_text
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	19	14208	16S	1529	1529	100.0	16S.l6.c17.ctg.1	2407	720.8	1	SNP	n	C1184T	0	.	.	1184	1184	C	1627	1627	C	830	C,A	829,1	16S.rDNA_WHO_F_01361c:0:1:C1184T:16S.1184T:E coli C1192T. Resistance to Spectinomycin	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	24246	23S	2890	2890	99.9	23S.l15.c4.ctg.1	4196	720.3	0	.	n	.	0	T695C	SNP	695	695	T	1311	1311	C	902	C,G	899,3	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	24246	23S	2890	2890	99.9	23S.l15.c4.ctg.1	4196	720.3	0	.	n	.	0	G1337A	SNP	1337	1337	G	1953	1953	A	1013	A,G	1012,1	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	24246	23S	2890	2890	99.9	23S.l15.c4.ctg.1	4196	720.3	0	.	n	.	0	T1971C	SNP	1971	1971	T	2587	2587	C	851	C,A,T	848,2,1	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	24246	23S	2890	2890	99.9	23S.l15.c4.ctg.1	4196	720.3	1	SNP	n	A2045G	0	.	.	2045	2045	A	2661	2661	A	793	A,C	791,1	23S.rDNA_WHO_F_01358c:0:1:A2045G:23S.2045G:E coli A2059G. High-level resistance to Azithromycin	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	24246	23S	2890	2890	99.9	23S.l15.c4.ctg.1	4196	720.3	1	SNP	n	C2597T	0	.	.	2597	2597	C	3213	3213	C	839	C,G,T	836,2,1	23S.rDNA_WHO_F_01358c:0:1:C2597T:23S.2597T :E coli C2611T. Low-level resistance to Azithromycin	.
folP.WHO_V_01427c	folP.WHO_V_01427c	1	1	27	2052	folP	855	855	100.0	folP.l15.c4.ctg.1	1936	132.1	1	SNP	p	R229S	1	.	.	685	687	AGC	1239	1241	AGC	223;222;223	A;G;C	223;222;223	folP.WHO_V_01427c:1:1:R229S:folP.228S:Resistance to sulphonamides	.
gyrA.WHO_M_01098	gyrA.WHO_M_01098	1	1	27	4574	gyrA	2751	2751	99.85	gyrA.l15.c4.ctg.1	3907	146.0	1	SNP	p	S91F	1	.	.	271	273	TTC	855	857	TTC	170;168;168	T,A;T,C,G;C,A	169,1;166,1,1;167,1	gyrA.WHO_M_01098:1:1:S91F:gyrA.91F:Resistance to fluoroquinolones	.
gyrA.WHO_M_01098	gyrA.WHO_M_01098	1	1	27	4574	gyrA	2751	2751	99.85	gyrA.l15.c4.ctg.1	3907	146.0	1	SNP	p	D95G	1	.	.	283	285	GGC	867	869	GGC	164;162;160	G,T,C;G,A,C;C,G	162,1,1;160,1,1;159,1	gyrA.WHO_M_01098:1:1:D95G:gyrA.95G:Resistance to fluoroquinolones	.
gyrA.WHO_M_01098	gyrA.WHO_M_01098	1	1	27	4574	gyrA	2751	2751	99.85	gyrA.l15.c4.ctg.1	3907	146.0	1	SNP	p	G95N	0	.	.	283	285	GGC	867	869	GGC	164;162;160	G,T,C;G,A,C;C,G	162,1,1;160,1,1;159,1	gyrA.WHO_M_01098:1:1:G95N:gyrA.95N:Resistance to fluoroquinolones	.
mtrR.WHO_O_01438	mtrR.WHO_O_01438	1	1	27	1862	mtrR	633	633	100.0	mtrR.l15.c4.ctg.1	1815	128.1	1	SNP	p	G45D	0	.	.	133	135	GGC	713	715	GGC	208;207;208	G;G;C,T	208;207;207,1	mtrR.WHO_O_01438:1:1:G45D:mtrR.45D:Increased efflux of antimicrobials, e.g. macrolides and b-lactam antimicrobials, that are substrates of the MtrCDE efflux pump	.
mtrR_promoter.WHO_F	mtrR_promoter.WHO_F	0	0	531	948	mtrR_promoter	250	250	99.6	mtrR_promoter.l15.c17.ctg.1	1466	80.7	0	.	n	.	0	A197.	DEL	197	197	A	875	875	A	184	A	184	.	.
parC.WHO_Y_00247c	parC.WHO_Y_00247c	1	1	27	4932	parC	2304	2304	100.0	parC.l6.c4.ctg.1	3322	184.5	1	SNP	p	D86N	0	.	.	256	258	GAC	750	752	GAC	200;200;197	G;A;C,T,A	200;200;195,1,1	parC.WHO_Y_00247c:1:1:D86N:parC.86N:Resistance to fluoroquinolones	.
parC.WHO_Y_00247c	parC.WHO_Y_00247c	1	1	27	4932	parC	2304	2304	100.0	parC.l6.c4.ctg.1	3322	184.5	1	SNP	p	R87W	0	.	.	259	261	CGT	753	755	CGT	197;194;195	C,A;G;T,G	195,2;194;194,1	parC.WHO_Y_00247c:1:1:R87W:parC.87W:Resistance to fluoroquinolones	.
parC.WHO_Y_00247c	parC.WHO_Y_00247c	1	1	27	4932	parC	2304	2304	100.0	parC.l6.c4.ctg.1	3322	184.5	1	SNP	p	R87I	0	.	.	259	261	CGT	753	755	CGT	197;194;195	C,A;G;T,G	195,2;194;194,1	parC.WHO_Y_00247c:1:1:R87I:parC.87I:Resistance to fluoroquinolones	.
parC.WHO_Y_00247c	parC.WHO_Y_00247c	1	1	27	4932	parC	2304	2304	100.0	parC.l6.c4.ctg.1	3322	184.5	1	SNP	p	S87R	1	.	.	259	261	CGT	753	755	CGT	197;194;195	C,A;G;T,G	195,2;194;194,1	parC.WHO_Y_00247c:1:1:S87R:parC.87R:Resistance to fluoroquinolones	.
parC.WHO_Y_00247c	parC.WHO_Y_00247c	1	1	27	4932	parC	2304	2304	100.0	parC.l6.c4.ctg.1	3322	184.5	1	SNP	p	S88P	0	.	.	262	264	TCC	756	758	TCC	195;194;194	T;C;C,A	195;194;193,1	parC.WHO_Y_00247c:1:1:S88P:parC.88P:Resistance to fluoroquinolones	.
parE.WHO_F_01528c	parE.WHO_F_01528c	1	1	27	4012	parE	1986	1986	100.0	parE.l15.c4.ctg.1	3121	160.2	1	SNP	p	G410V	0	.	.	1228	1230	GGC	1748	1750	GGC	223;221;218	G;G;C	223;221;218	parE.WHO_F_01528c:1:1:G410V:parE.410V:Resistance to fluoroquinolones	.
penA.5.002	penA.5.002	1	1	27	3746	penA	1752	1752	100.0	penA.l15.c4.ctg.1	2754	169.2	1	SNP	p	A311V	0	.	.	931	933	GCA	1448	1450	GCA	211;211;210	G;C;A	211;210;210	penA.5.002:1:1:A311V:penA.311V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.5.002	penA.5.002	1	1	27	3746	penA	1752	1752	100.0	penA.l15.c4.ctg.1	2754	169.2	1	SNP	p	I312M	0	.	.	934	936	ATC	1451	1453	ATC	207;202;202	A;T;C,G,T	207;202;198,3,1	penA.5.002:1:1:I312M:penA.312M:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.5.002	penA.5.002	1	1	27	3746	penA	1752	1752	100.0	penA.l15.c4.ctg.1	2754	169.2	1	SNP	p	V316T	0	.	.	946	948	GTG	1463	1465	GTG	216;216;217	G;T;G	216;216;217	penA.5.002:1:1:V316T:penA.316T:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.5.002	penA.5.002	1	1	27	3746	penA	1752	1752	100.0	penA.l15.c4.ctg.1	2754	169.2	1	SNP	p	V316P	0	.	.	946	948	GTG	1463	1465	GTG	216;216;217	G;T;G	216;216;217	penA.5.002:1:1:V316P:penA.316P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.5.002	penA.5.002	1	1	27	3746	penA	1752	1752	100.0	penA.l15.c4.ctg.1	2754	169.2	1	SNP	p	T484S	0	.	.	1450	1452	ACC	1967	1969	ACC	226;226;226	A;C;C	226;226;226	penA.5.002:1:1:T484S:penA.483S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.5.002	penA.5.002	1	1	27	3746	penA	1752	1752	100.0	penA.l15.c4.ctg.1	2754	169.2	1	SNP	p	A502V	0	.	.	1504	1506	GCG	2021	2023	GCG	213;214;217	G;C;G	213;214;217	penA.5.002:1:1:A502V:penA.501V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.5.002	penA.5.002	1	1	27	3746	penA	1752	1752	100.0	penA.l15.c4.ctg.1	2754	169.2	1	SNP	p	A502P	0	.	.	1504	1506	GCG	2021	2023	GCG	213;214;217	G;C;G	213;214;217	penA.5.002:1:1:A502P:penA.501P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.5.002	penA.5.002	1	1	27	3746	penA	1752	1752	100.0	penA.l15.c4.ctg.1	2754	169.2	1	SNP	p	G543S	1	.	.	1627	1629	AGC	2144	2146	AGC	202;202;202	A,G;G,C;C	200,2;201,1;202	penA.5.002:1:1:G543S:penA.542S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.5.002	penA.5.002	1	1	27	3746	penA	1752	1752	100.0	penA.l15.c4.ctg.1	2754	169.2	1	SNP	p	G546S	0	.	.	1636	1638	GGC	2153	2155	GGC	207;208;209	G;G;C,G	207;208;208,1	penA.5.002:1:1:G546S:penA.545S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.5.002	penA.5.002	1	1	27	3746	penA	1752	1752	100.0	penA.l15.c4.ctg.1	2754	169.2	1	SNP	p	P552S	0	.	.	1654	1656	CCG	2171	2173	CCG	208;209;209	C;C,A;G,A	208;208,1;208,1	penA.5.002:1:1:P552S:penA.551S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
ponA.WHO_G_00106	ponA.WHO_G_00106	1	1	27	4906	ponA	2397	2397	100.0	ponA.l15.c4.ctg.1	3603	169.5	1	SNP	p	L421P	1	.	.	1261	1263	CCG	1863	1865	CCG	192;192;192	C;C;G	192;192;192	ponA.WHO_G_00106:1:1:L421P:ponA.421P:High-level chromosomally-mediated penicillin resistance	.
porA.NCCP11945	porA.NCCP11945	1	0	531	2276	porA	1146	1146	99.91	porA.l15.c17.ctg.1	2276	124.4	0	.	p	.	0	M83fs	FSHIFT	247	247	A	783	783	C	194	C	194	.	.
porB1a.WHO_F_02106	porB1a.WHO_F_02106	1	0	528	242	porB1a	984	151	92.72	porB1a.l15.c17.ctg.1	151	44.6	0	.	p	.	0	V258L	NONSYN	772	774	GTA	10	12	TTA	20;23;23	T;T;A	20;23;23	.	.
porB1a.WHO_F_02106	porB1a.WHO_F_02106	1	0	528	242	porB1a	984	151	92.72	porB1a.l15.c17.ctg.1	151	44.6	0	.	p	.	0	S271T	NONSYN	811	813	TCG	49	51	ACT	54;54;54	A;C;T	54;54;54	.	.
porB1a.WHO_F_02106	porB1a.WHO_F_02106	1	0	528	242	porB1a	984	151	92.72	porB1a.l15.c17.ctg.1	151	44.6	0	.	p	.	0	Y273H	NONSYN	817	819	TAT	55	57	CAT	54;54;54	C,G;A;T	53,1;54;54	.	.
porB1a.WHO_F_02106	porB1a.WHO_F_02106	1	0	528	242	porB1a	984	151	92.72	porB1a.l15.c17.ctg.1	151	44.6	0	.	p	.	0	D274S	NONSYN	820	822	GAT	58	60	AGT	54;54;54	A;G;T	54;54;54	.	.
porB1a.WHO_F_02106	porB1a.WHO_F_02106	1	0	528	242	porB1a	984	151	92.72	porB1a.l15.c17.ctg.1	151	44.6	0	.	p	.	0	N277Y	NONSYN	829	831	AAC	67	69	TAC	54;54;54	T,C,A;A;C	52,1,1;54;54	.	.
porB1b.WHO_Z_02266c	porB1b.WHO_Z_02266c	1	1	539	2348	porB1b	1047	1047	96.76	porB1b.l6.c30.ctg.1	1938	150.4	0	.	p	.	0	G38E	NONSYN	112	114	GGA	616	618	GAA	181;180;181	G,C;A;A,G	180,1;180;180,1	.	.
porB1b.WHO_Z_02266c	porB1b.WHO_Z_02266c	1	1	539	2348	porB1b	1047	1047	96.76	porB1b.l6.c30.ctg.1	1938	150.4	0	.	p	.	0	R40W	NONSYN	118	120	CGG	622	624	TGG	180;183;181	T;G;G	179;182;180	.	.
porB1b.WHO_Z_02266c	porB1b.WHO_Z_02266c	1	1	539	2348	porB1b	1047	1047	96.76	porB1b.l6.c30.ctg.1	1938	150.4	0	.	p	.	0	T89S	NONSYN	265	267	ACC	769	771	AGC	210;207;208	A;G;C	210;207;208	.	.
porB1b.WHO_Z_02266c	porB1b.WHO_Z_02266c	1	1	539	2348	porB1b	1047	1047	96.76	porB1b.l6.c30.ctg.1	1938	150.4	0	.	p	.	0	.	MULTIPLE	358	359	AA	861	862	CG	164;162	C;G,A	164;161,1	.	.
porB1b.WHO_Z_02266c	porB1b.WHO_Z_02266c	1	1	539	2348	porB1b	1047	1047	96.76	porB1b.l6.c30.ctg.1	1938	150.4	0	.	p	.	0	.	MULTIPLE	361	362	GA	864	866	CAG	161;160;159	C,T;A,G;G,C,A,T	160,1;159,1;156,1,1,1	.	.
porB1b.WHO_Z_02266c	porB1b.WHO_Z_02266c	1	1	539	2348	porB1b	1047	1047	96.76	porB1b.l6.c30.ctg.1	1938	150.4	0	.	p	.	0	N122K	NONSYN	364	366	AAC	868	870	AAA	161;161;162	A,T;A,C;A,C,G	160,1;160,1;159,2,1	.	.
porB1b.WHO_Z_02266c	porB1b.WHO_Z_02266c	1	1	539	2348	porB1b	1047	1047	96.76	porB1b.l6.c30.ctg.1	1938	150.4	0	.	p	.	0	F131Y	NONSYN	391	393	TTT	895	897	TAT	181;181;181	T,A;A,C;T,G	180,1;180,1;180,1	.	.
porB1b.WHO_Z_02266c	porB1b.WHO_Z_02266c	1	1	539	2348	porB1b	1047	1047	96.76	porB1b.l6.c30.ctg.1	1938	150.4	0	.	p	.	0	N134E	NONSYN	400	402	AAT	904	906	GAG	180;180;181	G,C;A;G	179,1;180;181	.	.
porB1b.WHO_Z_02266c	porB1b.WHO_Z_02266c	1	1	539	2348	porB1b	1047	1047	96.76	porB1b.l6.c30.ctg.1	1938	150.4	0	.	p	.	0	V135F	NONSYN	403	405	GTG	907	909	TTT	181;182;181	T;T;T	181;182;181	.	.
porB1b.WHO_Z_02266c	porB1b.WHO_Z_02266c	1	1	539	2348	porB1b	1047	1047	96.76	porB1b.l6.c30.ctg.1	1938	150.4	0	.	p	.	0	V151A	NONSYN	451	453	GTA	955	957	GCA	194;194;195	G;C;A	194;194;195	.	.
porB1b.WHO_Z_02266c	porB1b.WHO_Z_02266c	1	1	539	2348	porB1b	1047	1047	96.76	porB1b.l6.c30.ctg.1	1938	150.4	0	.	p	.	0	Q187R	NONSYN	559	561	CAA	1063	1065	CGA	232;230;230	C,G,A;G,C;A,C	230,1,1;229,1;228,1	.	.
porB1b.WHO_Z_02266c	porB1b.WHO_Z_02266c	1	1	539	2348	porB1b	1047	1047	96.76	porB1b.l6.c30.ctg.1	1938	150.4	0	.	p	.	0	S189G	NONSYN	565	567	AGC	1069	1071	GGC	221;221;221	G;G,A,C;C,G	221;219,1,1;220,1	.	.
porB1b.WHO_Z_02266c	porB1b.WHO_Z_02266c	1	1	539	2348	porB1b	1047	1047	96.76	porB1b.l6.c30.ctg.1	1938	150.4	0	.	p	.	0	N212D	NONSYN	634	636	AAT	1138	1140	GAT	202;200;200	G,A;A,G;T,A	200,1;198,1;198,1	.	.
porB1b.WHO_Z_02266c	porB1b.WHO_Z_02266c	1	1	539	2348	porB1b	1047	1047	96.76	porB1b.l6.c30.ctg.1	1938	150.4	0	.	p	.	0	D213N	NONSYN	637	639	GAT	1141	1143	AAT	202;201;201	A;A;T	201;199;200	.	.
porB1b.WHO_Z_02266c	porB1b.WHO_Z_02266c	1	1	539	2348	porB1b	1047	1047	96.76	porB1b.l6.c30.ctg.1	1938	150.4	0	.	p	.	0	T215F	NONSYN	643	645	ACT	1147	1149	TTT	191;192;190	T;T,A;T	190;190,1;189	.	.
porB1b.WHO_Z_02266c	porB1b.WHO_Z_02266c	1	1	539	2348	porB1b	1047	1047	96.76	porB1b.l6.c30.ctg.1	1938	150.4	0	.	p	.	0	I218V	NONSYN	652	654	ATA	1156	1158	GTC	179;179;175	G,A;T;C	177,1;178;175	.	.
porB1b.WHO_Z_02266c	porB1b.WHO_Z_02266c	1	1	539	2348	porB1b	1047	1047	96.76	porB1b.l6.c30.ctg.1	1938	150.4	0	.	p	.	0	F222S	NONSYN	664	666	TTT	1168	1170	TCT	170;169;173	T;C,T;T	170;168,1;173	.	.
porB1b.WHO_Z_02266c	porB1b.WHO_Z_02266c	1	1	539	2348	porB1b	1047	1047	96.76	porB1b.l6.c30.ctg.1	1938	150.4	0	.	p	.	0	V242A	NONSYN	724	726	GTT	1228	1230	GCC	190;189;194	G;C;C	190;189;194	.	.
porB1b.WHO_Z_02266c	porB1b.WHO_Z_02266c	1	1	539	2348	porB1b	1047	1047	96.76	porB1b.l6.c30.ctg.1	1938	150.4	0	.	p	.	0	S292T	NONSYN	874	876	TCT	1378	1380	ACT	202;200;200	A;C;T	202;200;200	.	.
porB1b.WHO_Z_02266c	porB1b.WHO_Z_02266c	1	1	539	2348	porB1b	1047	1047	96.76	porB1b.l6.c30.ctg.1	1938	150.4	0	.	p	.	0	E328A	NONSYN	982	984	GAA	1486	1488	GCA	196;198;199	G;C;A	196;198;199	.	.
porB1b.WHO_Z_02266c	porB1b.WHO_Z_02266c	1	1	539	2348	porB1b	1047	1047	96.76	porB1b.l6.c30.ctg.1	1938	150.4	1	SNP	p	G120K	1	.	.	358	360	AAG	861	863	CGG	164;162;161	C;G,A;G	164;161,1;161	porB1b.WHO_Z_02266c:1:1:G120K:porB1b.120K:G101K. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
porB1b.WHO_Z_02266c	porB1b.WHO_Z_02266c	1	1	539	2348	porB1b	1047	1047	96.76	porB1b.l6.c30.ctg.1	1938	150.4	1	SNP	p	D121N	0	.	.	361	363	GAC	864	867	CGC	161;159;159	C,T;G,C,A,T;C	160,1;156,1,1,1;159	porB1b.WHO_Z_02266c:1:1:D121N:porB1b.121N:A102N. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
porB1b.WHO_Z_02266c	porB1b.WHO_Z_02266c	1	1	539	2348	porB1b	1047	1047	96.76	porB1b.l6.c30.ctg.1	1938	150.4	1	SNP	p	A121D	1	.	.	361	363	GAC	864	867	CGC	161;159;159	C,T;G,C,A,T;C	160,1;156,1,1,1;159	porB1b.WHO_Z_02266c:1:1:A121D:porB1b.121D:A102D. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
rpoB.WHO_M_02157	rpoB.WHO_M_02157	1	1	27	9476	rpoB	4179	4179	99.95	rpoB.l15.c4.ctg.1	5416	218.0	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
rpsJ.WHO_Y_02241	rpsJ.WHO_Y_02241	1	1	27	1304	rpsJ	312	312	100.0	rpsJ.l15.c4.ctg.1	1526	106.5	1	SNP	p	V57M	1	.	.	169	171	ATG	777	779	ATG	246;245;246	A,C;T;G	245,1;245;246	rpsJ.WHO_Y_02241:1:1:V57M:rpsJ.57M:Chromosomally-mediated resistance to tetracyclines	.
